Vas Narasimhan (Photographer: Simon Dawson/Bloomberg via Getty Images)
May 15, 2021 09:00 AM EDTUpdated May 21, 04:43 AM
Pharma

#ACC21: No­var­tis whiffs on En­tresto study af­ter heart at­tacks — but that does­n't mean it's go­ing down qui­et­ly

Kyle Blankenship

If No­var­tis learned one thing from its in­ter­ac­tion with the FDA over its lat­est heart fail­ure ap­proval for En­tresto, it was that miss­ing a pri­ma­ry …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times